Tech Company Financing Transactions
Veana Therapeutics Funding Round
Veana Therapeutics, based in Portland, raised $542 thousand from National Institutes of Health.
Transaction Overview
Company Name
Announced On
5/30/2018
Transaction Type
Venture Equity
Amount
$542,000
Round
Seed
Investors
Proceeds Purpose
The new money will fund the first clinical trial of Veana's lead drug candidate, Vimo -- a derivative of vitamin E that could make cutting-edge cancer immunotherapy drugs more effective, without the toxic side effects of chemo.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3720 SW Bond Ave. 508
Portland, OR 97239
USA
Portland, OR 97239
USA
Phone
Undisclosed
Website
Email Address
Overview
Veana Therapeutics, dedicated to developing innovative, safe, cancer fighting immunotherapeutic products. VEANA THERAPEUTICS, Inc. is a privately held Oregon-based biotechnology company whose business strategy is to identify a-TEA-based cancer immunotherapy technologies. Established in 2012, it is based on the work of its founder, Dr. Emmanuel Akporiaye.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emmanuel Akporiaye
Browse more venture capital transactions:
Prev: 5/30/2018: CTRL-Labs venture capital transaction
Next: 5/31/2018: Plum Wine venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs